| dbo:abstract |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. (en) |
| dbo:foundingYear |
1995-01-01 (xsd:gYear) |
| dbo:industry |
dbr:Pharmaceutical |
| dbo:location |
dbr:United_States dbr:The_Woodlands,_Texas |
| dbo:numberOfEmployees |
225 (xsd:nonNegativeInteger) |
| dbo:revenue |
3.241E8 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Lxrx.png?width=300 |
| dbo:type |
dbr:Public_company |
| dbo:wikiPageID |
12140543 (xsd:integer) |
| dbo:wikiPageLength |
10296 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1101682082 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Carcinoid_syndrome dbc:Pharmaceutical_companies_established_in_1995 dbr:Princeton,_New_Jersey dbr:Baylor_College_of_Medicine dbr:Houston dbr:Pharmaceutical dbr:Rheumatoid_arthritis dbr:United_States dbr:Public_company dbc:Companies_listed_on_the_Nasdaq dbc:Companies_based_in_The_Woodlands,_Texas dbr:Russell_2000_Index dbr:Gastroenterology dbr:Gene_knockout dbr:Gene_targeting dbr:Gene_trapping dbr:Nature_(journal) dbr:The_Woodlands,_TX dbr:The_Woodlands,_Texas dbr:Click_chemistry dbr:Clinical_trials dbr:Type_2_diabetes dbr:Irritable_bowel_syndrome dbr:Allan_Bradley dbc:2000_initial_public_offerings dbr:Deloitte_Fast_500 dbr:Telotristat_ethyl dbr:Texas dbc:Biopharmaceutical_companies dbc:Pharmaceutical_companies_of_the_United_States dbc:Health_care_companies_based_in_Texas dbr:Biological_target dbr:Biotechnology dbr:Mario_Capecchi dbr:Martin_Evans dbr:Human_Genome_Project dbr:Embryonic_stem_cells dbr:Immunology dbr:Metabolism dbr:New_Jersey dbr:Oliver_Smithies dbr:Oncology dbr:Ophthalmology dbr:Sotagliflozin dbr:Knockout_mice dbr:K._Barry_Sharpless dbr:File:Knockoutmouse80-72.jpg |
| dbp:foundation |
The Woodlands, TX, 1995 (en) |
| dbp:industry |
dbr:Pharmaceutical |
| dbp:keyPeople |
Jeffrey L. Wade, EVP of Corporate Development & Chief Scientific Officer (en) Lonnel Coats, president and chief executive officer (en) Alan J. Main, EVP of Pharmaceutical Research (en) James F. Tessmer, VP of Finance and Accounting (en) Pablo Lapuerta, EVP of Clinical Development & Chief Medical Officer (en) Brian P. Zambrowicz, EVP & Chief Scientific Officer (en) |
| dbp:location |
dbr:United_States dbr:The_Woodlands,_Texas |
| dbp:logo |
Lxrx.png (en) |
| dbp:name |
Lexicon Pharmaceuticals (en) |
| dbp:numEmployees |
225 (xsd:integer) |
| dbp:revenue |
3.241E8 |
| dbp:tradedAs |
dbr:Russell_2000_Index NASDAQ:LXRX (en) |
| dbp:type |
dbr:Public_company |
| dbp:wikiPageUsesTemplate |
dbt:Increase dbt:Infobox_company dbt:Url dbt:Pharmaceutical_companies_of_the_United_States |
| dbp:wordnet_type |
http://www.w3.org/2006/03/wn/wn20/instances/synset-company-noun-1 |
| dcterms:subject |
dbc:Pharmaceutical_companies_established_in_1995 dbc:Companies_listed_on_the_Nasdaq dbc:Companies_based_in_The_Woodlands,_Texas dbc:2000_initial_public_offerings dbc:Biopharmaceutical_companies dbc:Pharmaceutical_companies_of_the_United_States dbc:Health_care_companies_based_in_Texas |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 yago:WikicatCompaniesBasedInTheWoodlands,Texas yago:WikicatCompaniesEstablishedIn1995 yago:WikicatCompaniesInTheNASDAQBiotechnologyIndex yago:WikicatCompaniesListedOnNASDAQ yago:Abstraction100002137 yago:Company108058098 yago:DrugCompany108002578 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity dbo:Organisation yago:SocialGroup107950920 yago:WikicatPharmaceuticalCompaniesOfTheUnitedStates |
| rdfs:comment |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, meta (en) |
| rdfs:label |
Lexicon Pharmaceuticals (en) |
| owl:sameAs |
freebase:Lexicon Pharmaceuticals yago-res:Lexicon Pharmaceuticals wikidata:Lexicon Pharmaceuticals https://global.dbpedia.org/id/4ppt3 |
| skos:closeMatch |
http://www.grid.ac/institutes/grid.417425.1 |
| prov:wasDerivedFrom |
wikipedia-en:Lexicon_Pharmaceuticals?oldid=1101682082&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Knockoutmouse80-72.jpg wiki-commons:Special:FilePath/Lxrx.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:Lexicon_Pharmaceuticals |
| foaf:name |
Lexicon Pharmaceuticals (en) |
| is dbo:wikiPageDisambiguates of |
dbr:Lexicon_(disambiguation) |
| is dbo:wikiPageRedirects of |
dbr:Lexicon_genetics |
| is dbo:wikiPageWikiLink of |
dbr:Research_and_Development_Council_of_New_Jersey dbr:The_Woodlands,_Texas dbr:Hartmuth_C._Kolb dbr:Telotristat_ethyl dbr:New_Enterprise_Associates dbr:Lexicon_(disambiguation) dbr:Sotagliflozin dbr:Lexicon_genetics |
| is foaf:primaryTopic of |
wikipedia-en:Lexicon_Pharmaceuticals |
